BioSpace News Archive

New results presented at the American Medical Society for Sports Medicine 2021 Annual Meeting find runners who had more gradual increases in weekly mileage had fewer injuries

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its paid tests based on the cancer differentiation analysis technology (CDA) technology, or paid CDA-based tests,

Select Medical Holdings Corporation (“Select Medical”) (NYSE: SEM) today announced the appointment of Katherine R. Davisson to its Board of Directors (the “Board”), effective immediately.

Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.

Tampa General Hospital announced Eduardo M. Sotomayor, MD, as the director of its newly established Cancer Institute to provide world-class, innovative cancer care in one of Florida’s leading academic medical centers.

Issue SteriMax Inc. is recalling OrfenAce 100 mg tablets after testing identified a nitrosamine impurity above what is considered acceptable if the drug were to be taken over a lifetime.

SecuSeal™ digital health card provides immediate, more secure proof of vaccination status while protecting privacy.

Arena Pharmaceuticals, Inc. announced that on April 15, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 50,785 shares of its common stock and 20,490 inducement restricted stock units.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides strong indications for analogous success in similar technology the Company is helping to develop.

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer